FOR IMMEDIATE RELEASE
RANCHO CORDOVA, Ca. (August 27, 2024) – SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced the appointment of Patrick Mahieux as President of Cell and Gene, Europe. Based in Paris at Yposkesi, an SK pharmteco company, Mahieux will lead the company’s cell and gene therapy business across the region.
Mahieux brings a wealth of experience in the pharmaceutical industry to SK pharmteco. Most recently, he served as CEO of ABL Europe where he successfully drove a 30% yearly growth from 2016 to 2022 by doubling the company’s capacity through strategic site acquisitions. His expertise in scaling operations and driving business growth will be instrumental in expanding SK pharmteco’s footprint in the European cell and gene therapy market.
“We are thrilled to welcome Patrick to SK pharmteco,” said Joerg Ahlgrimm, CEO of SK pharmteco. “His impressive career and deep industry expertise align perfectly with our strategic goals. We are confident that under his leadership as President of Yposkesi, we will significantly expand our cell and gene therapy business in Europe and continue to deliver exceptional value to our clients.”
With a doctorate in pharmacy from Paris University and a master’s degree in pharmaceutical industrial technology and biopharmacy from Paris-Sud University, Mahieux has a deep understanding of the pharmaceutical landscape and a proven track record of success. His extensive knowledge, combined with his leadership skills, make him an invaluable asset to the SK pharmteco team.
“I am excited to join SK pharmteco and contribute to the company’s growth in Europe,” said Mahieux. “SK pharmteco has a strong reputation for excellence and innovation, and I am eager to work with the talented team at SK pharmteco to build upon our shared commitment to advancing patient care and bringing life-saving therapies to patients worldwide.”
###
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with 18 production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
Contact:
Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com
Website: www.skpharmteco.com
SOURCE: SK pharmteco
